Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPASSOS-CASTILHO, Ana Maria
dc.contributor.authorCARVALHO, Valdemir Melechco
dc.contributor.authorCARDOZO, Karina Helena Morais
dc.contributor.authorKIKUCHI, Luciana
dc.contributor.authorCHAGAS, Aline Lopes
dc.contributor.authorGOMES-GOUVEA, Michele Soares
dc.contributor.authorMALTA, Fernanda
dc.contributor.authorNASTRI, Ana Catharina de Seixas-Santos
dc.contributor.authorPINHO, Joao Renato Rebello
dc.contributor.authorCARRILHO, Flair Jose
dc.contributor.authorGRANATO, Celso Francisco Hernandes
dc.date.accessioned2016-02-11T14:09:14Z
dc.date.available2016-02-11T14:09:14Z
dc.date.issued2015
dc.description.abstractBackground: Chronic hepatitis B (CHB) virus infection is a major cause of hepatocellular carcinoma (HCC), as late diagnosis is the main factor for the poor survival of patients. There is an urgent need for accurate biomarkers for early diagnosis of HCC. The aim of the study was to explore the serum lipidome profiles of hepatitis B-related HCC to identify potential diagnostic biomarkers. Methods: An ultraperformance liquid chromatography mass spectrometry (UPLC-MS) lipidomic method was used to characterize serum profiles from HCC (n = 32), liver cirrhosis (LC) (n = 30), CHB (n = 25), and healthy subjects (n = 34). Patients were diagnosed by clinical laboratory and imaging evidence and all presented with CHB while healthy controls had normal liver function and no infectious diseases. Results: The UPLC-MS-based serum lipidomic profile provided more accurate diagnosis for LC patients than conventional alpha-fetoprotein (AFP) detection. HCC patients were discriminated from LC with 78 % sensitivity and 64 % specificity. In comparison, AFP showed sensitivity and specificity of 38 % and 93 %, respectively. HCC was differentiated from CHB with 100 % sensitivity and specificity using the UPLC-MS approach. Identified lipids comprised glycerophosphocolines, glycerophosphoserines and glycerophosphoinositols. Conclusions: UPLC-MS lipid profiling proved to be an efficient and convenient tool for diagnosis and screening of HCC in a high-risk population.
dc.description.indexMEDLINE
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP [2013/03701-0]
dc.description.sponsorshipFleury SA Group
dc.identifier.citationBMC CANCER, v.15, article ID 985, 9p, 2015
dc.identifier.doi10.1186/s12885-015-1995-1
dc.identifier.issn1471-2407
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/12701
dc.language.isoeng
dc.publisherBIOMED CENTRAL LTD
dc.relation.ispartofBMC Cancer
dc.rightsopenAccess
dc.rights.holderCopyright BIOMED CENTRAL LTD
dc.subjectBiomarker
dc.subjectHepatocellular carcinoma
dc.subjectHepatitis B
dc.subjectLipidomics
dc.subjectUPLC-MS
dc.subjectDiagnosis
dc.subject.otherepidemiologic aspects
dc.subject.othercirrhosis
dc.subject.othermetabolism
dc.subject.otherplasma
dc.subject.otherbrazil
dc.subject.othervirus
dc.subject.otherliver
dc.subject.wosOncology
dc.titleSerum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalPASSOS-CASTILHO, Ana Maria:Univ Fed Sao Paulo, Div Infect Dis, BR-04039032 Sao Paulo, SP, Brazil
hcfmusp.author.externalCARVALHO, Valdemir Melechco:Fleury Grp, Sao Paulo, SP, Brazil
hcfmusp.author.externalCARDOZO, Karina Helena Morais:Fleury Grp, Sao Paulo, SP, Brazil
hcfmusp.author.externalGRANATO, Celso Francisco Hernandes:Univ Fed Sao Paulo, Div Infect Dis, BR-04039032 Sao Paulo, SP, Brazil; Fleury Grp, Sao Paulo, SP, Brazil
hcfmusp.citation.scopus19
hcfmusp.contributor.author-fmusphcLUCIANA OBA ONISHI KIKUCHI
hcfmusp.contributor.author-fmusphcALINE LOPES CHAGAS
hcfmusp.contributor.author-fmusphcMICHELE SOARES GOMES GOUVEA
hcfmusp.contributor.author-fmusphcFERNANDA DE MELLO MALTA
hcfmusp.contributor.author-fmusphcANA CATHARINA DE SEIXAS SANTOS NASTRI
hcfmusp.contributor.author-fmusphcJOAO RENATO REBELLO PINHO
hcfmusp.contributor.author-fmusphcFLAIR JOSE CARRILHO
hcfmusp.description.articlenumber985
hcfmusp.description.volume15
hcfmusp.origemWOS
hcfmusp.origem.pubmed26680993
hcfmusp.origem.scopus2-s2.0-84949996479
hcfmusp.origem.wosWOS:000366901300003
hcfmusp.publisher.cityLONDON
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceBolondi L, 2003, J HEPATOL, V39, P1076, DOI 10.1016/S0168-8278(03)00349-0
hcfmusp.relation.referencePatterson AD, 2011, CANCER RES, V71, P6590, DOI 10.1158/0008-5472.CAN-11-0885
hcfmusp.relation.referenceSullentrop F, 2002, NMR BIOMED, V15, P60, DOI 10.1002/nbm.758
hcfmusp.relation.referenceKikuchi L, 2013, ANTIVIR THER, V18, P445, DOI 10.3851/IMP2602
hcfmusp.relation.referenceFerlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
hcfmusp.relation.referenceKim CK, 2001, J ULTRAS MED, V20, P99
hcfmusp.relation.referenceSingal A, 2009, ALIMENT PHARM THER, V30, P37, DOI 10.1111/j.1365-2036.2009.04014.x
hcfmusp.relation.referenceBLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
hcfmusp.relation.referenceCarrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
hcfmusp.relation.referenceWang BH, 2012, J PROTEOME RES, V11, P1217, DOI 10.1021/pr2009252
hcfmusp.relation.referenceZhou LN, 2012, ANAL BIOANAL CHEM, V403, P203, DOI 10.1007/s00216-012-5782-4
hcfmusp.relation.referenceOtt JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
hcfmusp.relation.referenceHu CX, 2009, J CHROMATOGR B, V877, P2836, DOI 10.1016/j.jchromb.2009.01.038
hcfmusp.relation.referenceWenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776
hcfmusp.relation.referenceMcGlynn KA, 2015, CLIN LIVER DIS, V19, P223, DOI 10.1016/j.cld.2015.01.001
hcfmusp.relation.referenceBruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
hcfmusp.relation.referenceDiamond DL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000719
hcfmusp.relation.referenceEl-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
hcfmusp.relation.referenceLlovet JM, 2012, J HEPATOL, V56, P908
hcfmusp.relation.referenceKimhofer T, 2015, BRIT J CANCER, V112, P1141, DOI 10.1038/bjc.2015.38
hcfmusp.relation.referenceLewen Jia JC, 2008, METABOLOMICS, V4, P183
hcfmusp.relation.referenceOehler N, 2014, HEPATOLOGY, V60, P1483, DOI 10.1002/hep.27159
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication77dba884-768d-484a-852d-385d38020bf4
relation.isAuthorOfPublication0319f3cd-c3b4-4360-bd40-594f8b8b99d2
relation.isAuthorOfPublication40082688-92fd-4f91-8d9f-44c85088369d
relation.isAuthorOfPublicationa9324386-13b6-4aae-8f0c-8273588275c3
relation.isAuthorOfPublication177403b6-b941-4ca0-bf8e-205e036686d2
relation.isAuthorOfPublication0ada2eb1-5ac2-4e40-b4e2-6af14f33268b
relation.isAuthorOfPublication9221b8d6-ad80-46e5-a56f-fb3b28a8c155
relation.isAuthorOfPublication.latestForDiscovery77dba884-768d-484a-852d-385d38020bf4
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_PASSOS-CASTILHO_Serum_lipidomic_profiling_as_a_useful_tool_for_2015.PDF
Tamanho:
2.53 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03